Must be getting close to both of these:
"Ongoing preparations for the initiation of the phase I
Maximal Use clinical trial (MUsT HXP124-ONY-003) to be
conducted in the US.This study is expected to start in mid
2022;
Continued steady progress towards completion of the phase
II study (HXP124-ONY-002) and results announcement on
schedule for Q2 2022."
Especially looking forward to the latter.
Ann: Quarterly Activities Report and Appendix 4C, page-5
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
